YARDLEY, Pa., Mar. 15, 2018 Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Optinose was named the Emerging Company of the Year by Life Sciences Pennsylvania at its Annual Dinner last night. Additionally, at the ceremony and as previously announced, CEO Peter Miller was presented with the 2017 Frank Baldino Bioscience CEO of the Year by Life Sciences Pennsylvania.
“I am thrilled and so proud of our team for winning this award,” said Optinose CEO Peter Miller. “At Optinose, we are maniacally focused on developing important products for patients, hiring exceptional colleagues and creating an environment in which those exceptional colleagues can accomplish even greater things together. As good a year as 2017 was for Optinose, we are focused on making 2018 even better. We thank Life Sciences Pennsylvania for this honor and for its important work that drives our dynamic and vibrant bioscience industry.”
The Life Sciences Pennsylvania Emerging Company of the Year Award recognizes a company or organization of 100 employees or less with significant operations in Pennsylvania that has experienced significant growth and/or achievement in 2017, while contributing positively to its community and the overall life sciences business climate of the Commonwealth.
Optinose is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. Optinose has offices in the U.S., the U.K. and Norway. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn.
Optinose Investor Contact
Optinose Media Contact
Kate Traynor, Sloane & Company